CORT (corcept.com) Market Value to Book Value Ratio

Official company branding of Corcept Therapeutics Inc. (CORT)

The price history of Corcept Therapeutics (CORT) serves as an indicator for a business focused on mifepristone that minimizes costs through outsourced production, although it is currently facing acute patent disputes regarding Korlym. The metric stands at 13.38. This biopharmaceutical firm treats complex metabolic disorders, where colossal investments in science are offset by ultra-high profitability upon the release of high-demand medications.

CORT Corcept Therapeutics Corp: Market Value to Book Value in the range 07/04/2022 - 10/28/2026

Financial and market metric breakdowns for Corcept Therapeutics Inc. (CORT)

- price and consensus price forecast:
Stock Quotes Corcept Therapeutics|CORT - Analyst Forecast Prices
- market capitalization data:
Market Value Corcept|CORT - Full Business Value
- book capitalization data:
Book Value per Share Corcept Therapeutics|CORT - Accounting Value of Company|Market Capitalization to Book Value Ratio corcept.com|CORT - Company Total Assets
- debt and liquidity data:
Debt to Equity Corcept Therapeutics|CORT - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Corcept|CORT - Company Total Debt|Debts to Book Capitalization Corcept|CORT - Company Long-Term Debts|Company Current Liabilities Corcept Therapeutics
Initial company analysis:Corcept Therapeutics - CORT
Original product of Corcept

Corcept Therapeutics' bet on an elite staff of endocrinologists creates high intellectual capital value that often exceeds formal balance sheet items. This ratio compares the business's market value to its net assets, determining whether the price includes a premium for unique developments or if the stock is undervalued, which is clearly reflected in the price-to-book value chart.

Main competitors

ASND - Market Cap to Net Assets Ratio|MDGL (madrigalpharma.com) - Market Cap to Book Value Multiple|Market Value to Book Value Ratio Rhythm Pharmaceuticals, Inc. RYTM|Market Capitalization to Net Assets Akero Therapeutics, Inc.|Metsera Corp (MTSR) - Market Capitalization to Book Value Ratio|Market Value to Book Value MoonLake Corp (MLTX)|Market Capitalization to Book Value Ratio CRNX (Crinetics Pharmaceuticals)|newamsterdampharma.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Soleno Therapeutics, Inc. (SLNO)|FOLD: Market Value to Book Value|ETNB (89bio Corp) - Market Value to Book Value Ratio|Agios Corp (AGIO) - Market Cap to Net Assets Ratio|GPCR (Structure Therapeutics) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio mimedx.com (MDXG)|Rezolute (RZLT) - Market Cap to Net Assets Ratio|Market Value to Book Value LXRX (Lexicon Pharmaceuticals Inc)|MBX Bio - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Altimmune Pharma ALT|AARD (Aardvark Therapeutics Inc) - Market Capitalization to Book Value Ratio|sagimet.com (SGMT) - Market-to-Book Ratio|BIOA - Market Cap to Net Assets Ratio|Biomea Fusion Inc (BMEA) - Market Cap to Book Value Multiple|QNCX (Quince Therapeutics Inc) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio Fractyl Health, Inc|Market Capitalization to Book Value Ratio vTv Therapeutics Inc. (VTVT)|Market Value to Book Value Ratio ATPC (agapeatpgroup.com)|PLUR: Market Value to Book Value Ratio|Synlogic Inc. - Market-to-Book Ratio|LPCN - Market Value to Book Value Ratio|MTNB - Market Value to Book Value Ratio|Spruce Biosciences - Market Capitalization to Book Value Ratio|GLTO (galecto.com) - Market Capitalization to Book Value|CTCX: Market Value to Book Value Ratio|Market Capitalization to Book Value LUMO|Market Value to Book Value Ratio ONVO (Organovo Holdings Inc)|Market Cap to Net Assets Ratio Radius Pharmaceuticals (RDUS)